Research News: CALR described as immunotherapy target

In an abstract submission to the academic journal Leukemia, Hans Hasselbach and colleagues describe CALR as a good target for development of an immunotherapy treatment for MPN. This is following up on the 2013 discovery of the CALR mutation, which accounts for the majority of JAK2 negative MPN patients. 

Click here to read the abstract submitted for full publication at a later date.

Click here to read about the initial CALR discovery.

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe